<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T10:19:40Z</responseDate>
  <request identifier="oai:figshare.com:article/34035007" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34035007</identifier>
        <datestamp>2026-09-30T17:30:09Z</datestamp>
        <setSpec>category_4</setSpec>
        <setSpec>category_8</setSpec>
        <setSpec>category_12</setSpec>
        <setSpec>category_14</setSpec>
        <setSpec>category_19</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_272</setSpec>
        <setSpec>category_873</setSpec>
        <setSpec>category_39</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_135</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;LC–MS analysis of OL extract.&lt;/p&gt;</dc:title>
          <dc:creator>Fadwa M. Arafa (25145191)</dc:creator>
          <dc:creator>Mohamed Hagar (7347941)</dc:creator>
          <dc:creator>Ahmed Zakaria (6164612)</dc:creator>
          <dc:creator>Eman Sheta (12250849)</dc:creator>
          <dc:creator>Nehal N. Hezema (25145194)</dc:creator>
          <dc:subject>Biochemistry</dc:subject>
          <dc:subject>Microbiology</dc:subject>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Molecular Biology</dc:subject>
          <dc:subject>Pharmacology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Environmental Sciences not elsewhere classified</dc:subject>
          <dc:subject>Chemical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Ecology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Computational  Biology</dc:subject>
          <dc:subject>severely deformed ones</dc:subject>
          <dc:subject>scanning electron microscopy</dc:subject>
          <dc:subject>restored villus architecture</dc:subject>
          <dc:subject>new therapeutic avenue</dc:subject>
          <dc:subject>lc – ms</dc:subject>
          <dc:subject>grave risk posed</dc:subject>
          <dc:subject>goblet cell count</dc:subject>
          <dc:subject>div &gt;&lt; p</dc:subject>
          <dc:subject>current research focused</dc:subject>
          <dc:subject>statistically significant rise</dc:subject>
          <dc:subject>serum mda levels</dc:subject>
          <dc:subject>regarding oocyst count</dc:subject>
          <dc:subject>intestinal villi revealed</dc:subject>
          <dc:subject>combating intestinal cryptosporidiosis</dc:subject>
          <dc:subject>similar ultrastructural alterations</dc:subject>
          <dc:subject>bacillus clausii &lt;/</dc:subject>
          <dc:subject>th &lt;/ sup</dc:subject>
          <dc:subject>intestinal cryptosporidiosis</dc:subject>
          <dc:subject>clausii &lt;/</dc:subject>
          <dc:subject>oocyst reduction</dc:subject>
          <dc:subject>mean levels</dc:subject>
          <dc:subject>corresponding rise</dc:subject>
          <dc:subject>vivo &lt;/</dc:subject>
          <dc:subject>clausii -&lt;/</dc:subject>
          <dc:subject>vulnerable populations</dc:subject>
          <dc:subject>treated group</dc:subject>
          <dc:subject>synergistic potential</dc:subject>
          <dc:subject>proficient use</dc:subject>
          <dc:subject>mass spectrometry</dc:subject>
          <dc:subject>lymphocytic population</dc:subject>
          <dc:subject>liquid chromatography</dc:subject>
          <dc:subject>incensole isomers</dc:subject>
          <dc:subject>immunosuppressed mice</dc:subject>
          <dc:subject>histopathological findings</dc:subject>
          <dc:subject>highest percentage</dc:subject>
          <dc:subject>extensive pits</dc:subject>
          <dc:subject>either alone</dc:subject>
          <dc:subject>day post</dc:subject>
          <dc:subject>complete distortion</dc:subject>
          <dc:subject>combined therapy</dc:subject>
          <dc:subject>chemical composition</dc:subject>
          <dc:subject>best results</dc:subject>
          <dc:subject>&gt;, ranging</dc:subject>
          <dc:subject>6 %),</dc:subject>
          <dc:description>&lt;div&gt;&lt;p&gt;Given the grave risk posed by intestinal cryptosporidiosis to vulnerable populations, the current research focused on a new therapeutic avenue. Olibanum (OL) extract and probiotic &lt;i&gt;Bacillus clausii&lt;/i&gt; (&lt;i&gt;B. clausii&lt;/i&gt;) and their combination were evaluated against &lt;i&gt;Cryptosporidium in vivo&lt;/i&gt; in immunosuppressed mice via parasitological, ultrastructural, biochemical, and histopathological analysis. Liquid chromatography-mass spectrometry (LC–MS) analysis of OL revealed the predominance of incensole isomers in its chemical composition. Regarding oocyst count in stool, the highest percentage of oocyst reduction was achieved after combined therapy (98.4%) on the 19&lt;sup&gt;th&lt;/sup&gt; day post-infection, followed by &lt;i&gt;B. clausii-&lt;/i&gt;treated group (87.6%), then the OL-treated group (87%). Similar ultrastructural alterations were noticed by scanning electron microscopy (SEM) following treatment by both OL and &lt;i&gt;B. clausii&lt;/i&gt;, ranging from shrunken oocysts to severely deformed ones with extensive pits or protrusions. Nonetheless, their combination resulted in complete distortion of the oocysts, leading to their rupture. Biochemically, both OL and &lt;i&gt;B. clausii&lt;/i&gt; treatment, either alone or in combination, provoked a decrease in the serum MDA levels, together with a corresponding rise in the mean levels of GSH. Concerning the histopathological findings, the best results were achieved following the combined OL and &lt;i&gt;B. clausii&lt;/i&gt; treatment, which has restored villus architecture and remarkably ameliorated detrimental intestinal inflammation and goblet cell count. Finally, immunohistochemical analysis of the lymphocytic population of the intestinal villi revealed a statistically significant rise in the CD4+ /CD8+ ratio after treatment with either OL, &lt;i&gt;B. clausii&lt;/i&gt; or their combination, which signals their proficient use for this therapeutic endeavour.&lt;/p&gt;&lt;/div&gt;</dc:description>
          <dc:date>2026-09-30T17:29:57Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1371/journal.pntd.0014734.t001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_p_LC_MS_analysis_of_OL_extract_p_/34035007</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
